Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6517
    -0.0019 (-0.29%)
     
  • OIL

    83.11
    +1.76 (+2.16%)
     
  • GOLD

    2,254.80
    +42.10 (+1.90%)
     
  • Bitcoin AUD

    108,684.41
    +2,642.35 (+2.49%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6037
    +0.0006 (+0.11%)
     
  • AUD/NZD

    1.0903
    +0.0023 (+0.22%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this vaccine maker have returned -23.6%, compared to the Zacks S&P 500 composite's +6.2% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Novavax falls in, has gained 8.7%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate Revisions

Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

ADVERTISEMENT

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Novavax is expected to post a loss of $0.53 per share for the current quarter, representing a year-over-year change of +95.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -141.8%.

For the current fiscal year, the consensus earnings estimate of -$5.19 points to a change of +77.9% from the prior year. Over the last 30 days, this estimate has changed -3701.4%.

For the next fiscal year, the consensus earnings estimate of -$5.85 indicates a change of -12.8% from what Novavax is expected to report a year ago. Over the past month, the estimate has changed +107.5%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Novavax.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

12-month consensus EPS estimate for NVAX _12MonthEPSChartUrl
12-month consensus EPS estimate for NVAX _12MonthEPSChartUrl

Projected Revenue Growth

While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Novavax, the consensus sales estimate of $418.05 million for the current quarter points to a year-over-year change of +88.1%. The $2.03 billion and $1.31 billion estimates for the current and next fiscal years indicate changes of +76.8% and -35.5%, respectively.

Last Reported Results and Surprise History

Novavax reported revenues of $734.58 million in the last reported quarter, representing a year-over-year change of +310.8%. EPS of -$2.15 for the same period compares with -$4.31 a year ago.

Compared to the Zacks Consensus Estimate of $551.68 million, the reported revenues represent a surprise of +33.15%. The EPS surprise was -197.29%.

The company could not beat consensus EPS estimates in any of the last four quarters. The company topped consensus revenue estimates just once over this period.

Valuation

No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Novavax is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Conclusion

The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Novavax. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novavax, Inc. (NVAX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research